Skip to main content
. Author manuscript; available in PMC: 2023 Mar 18.
Published in final edited form as: Med Decis Making. 2022 Dec 13;43(3):337–349. doi: 10.1177/0272989X221143058

Figure 3/.

Figure 3/

Decision curve analysis plot, for a range of threshold values for natalizumab (19%-40%) and equal constant threshold values for dimethyl fumarate and glatiramer acetate (10%). X-axis represents the range of threshold values for natalizumab, and y-axis represents the net benefit for each one of the five strategies: ‘Treat none’, ‘treat based on the model’, ‘treat all with natalizumab’, ‘treat all with dimethyl fumarate’ and ‘treat all with glatiramer cetate’. (Dashed black line represents the highest net benefit)